Abstract 357: Detailed mechanistic understanding of ACR-2316, a novel, clinical-stage WEE1/PKMYT1 inhibitor, rationally designed for superior single-agent activity through potent activation of CDK1, CDK2, and PLK1 using Acrivon’s machine learning-driven AP3 platform
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Lei Shi, Martina Pasetto, Mohamed Eldeeb, Reina Improgo, Shahrzad Rafiei, Maria Rodriguez Zabala, Calvin Yang, Ahmed Youssef, Georgia Mitsa, Nina Lipjankić, Anna-Maria Alves, Portia Lombardo, Jessica Hopkins, Bryan Thornlow, William Dahlberg, Everett Hay, Ignacio Arribas Díez, Marc Isaksson, Zachary Best, Chris S. Balagtas, Corey Xu, Magnus E. Jakobsson, Helén Nilsson, Joon Jung, Caroline Wigerup, David A. Proia, Kristina Masson, Peter Blume-Jensen
Institutions: Medicon Village, Active Motif (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409634523